Stocks · News reference

Bright Minds Biosciences shares are trading higher after Wolfe Research initiated its coverage on the stock with an Outperform rating and announced a price target of $150.

Oct 15, 2026, 5:07 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 15, 2026, 11:55 AMBenzinga Newsdesk
Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150
Wolfe Research initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $150.
DRUG
BenzingaAug 19, 2026, 3:12 PMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.
DRUG
BenzingaAug 17, 2026, 4:24 PMBenzinga Newsdesk
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
DRUG